Olmesartan Medoxomil Teva Italia

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil Teva Italia, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is used to treat hypertension in adult patients, helping to lower elevated blood pressure and reduce the risk of cardiovascular complications.

GNH USA supplies Olmesartan Medoxomil Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution. The company ensures product integrity through rigorous quality control and timely logistics.

Olmesartan medoxomil is an Angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure, providing long‑term control. - Cardiovascular risk reduction: helps decrease the likelihood of stroke and heart attack in hypertensive patients. - Renal protection in hypertension: may slow progression of kidney damage associated with high blood pressure.

Olmesartan medoxomil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Hyperkalemia (elevated blood potassium) - Acute kidney injury - Severe hypotension - Liver enzyme elevation

Use olmesartan with caution and follow medical guidance.

- Pregnancy: Category D – avoid use during pregnancy due to fetal risk. - Renal impairment: monitor kidney function and adjust dose if needed. - Hyperkalemia: check serum potassium levels, especially when combined with potassium‑sparing agents. - Concomitant diuretics: may increase risk of hypotension; monitor blood pressure. - Drug interactions: review all concomitant medications for potential interactions. - Store at room temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Olmesartan may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Aliskiren (in diabetic patients) – increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements – may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – can reduce antihypertensive effect and impair renal function. - Lithium – may increase lithium levels, risking toxicity. - Other antihypertensives (e.g., ACE inhibitors, beta‑blockers) – may cause additive blood‑pressure lowering. - Diuretics – may enhance hypotensive effect, requiring dose adjustment.